Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

医学 液体活检 活检 一致性 肺癌 肿瘤科 癌症 内科学 病理
作者
Luis Estuardo Raez,Kayla Brice,Katerine Dumais,Alejandro Lopez-Cohen,Delia A Wietecha,Paola A. Izquierdo,Edgardo S. Santos,H. Powery
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:24 (2): 120-129 被引量:125
标识
DOI:10.1016/j.cllc.2022.11.007
摘要

In the last decade, non–small-cell lung cancer (NSCLC) treatment has improved with the approval of multiple therapies to target specific genetic alterations. Though, next generation sequencing (NGS) has traditionally been conducted from tissue biopsy samples, developing data supports the use of plasma-based circulating tumor DNA (ctDNA), also known as “liquid biopsy,” to complement tissue biopsy approaches in guiding front-line therapy. This study is a retrospective analysis of 170 new NSCLC patients treated at 2 cancer centers within a 5-year period who received both tissue and liquid biopsy NGS as standard of care. Based on a treatment schema defined by testing sufficiency, biomarker detection, and turnaround time (TAT), physicians based the majority of their treatments on liquid biopsy results (73.5%) versus tissue biopsy (25.9%). Liquid biopsy NGS returned results on average 26.8 days faster than tissue and reported higher testing success. For guideline-recommended biomarkers, liquid biopsy was 94.8% to 100% concordant with tissue. In comparing testing modalities, a liquid-first approach identified guideline-recommended biomarkers in 76.5% of patients versus 54.9% in a tissue-first approach. There was no significant difference in time-to-treatment, or survival outcomes (overall survival and progression free survival) based on liquid versus tissue biopsy findings. This research demonstrates that liquid biopsy NGS is an effective tool to capture actionable genetic alterations in NSCLC. Due to its high concordance to tissue, faster TAT, and similarity in outcomes and time-to-treatment, liquid biopsy can be used either as a first-line test or concordantly with tissue biopsy to guide treatment decisions in NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欢喜霸完成签到 ,获得积分10
刚刚
刚刚
Geng完成签到,获得积分10
刚刚
勤奋柜子完成签到,获得积分10
刚刚
可爱的函函的应助被沙拉酱采纳,获得10
刚刚
陈钧完成签到,获得积分10
刚刚
张无凡完成签到,获得积分10
刚刚
李wf完成签到,获得积分10
1秒前
小巧的柚子完成签到,获得积分10
1秒前
DeepSleep完成签到,获得积分10
1秒前
1秒前
可爱夜雪完成签到,获得积分10
1秒前
yj发布了新的文献求助10
1秒前
changzm完成签到,获得积分10
1秒前
蔚岚影落完成签到,获得积分10
2秒前
vvvvvv完成签到,获得积分10
3秒前
null的应助被hzs采纳,获得10
3秒前
ZYLOOONG完成签到,获得积分10
3秒前
左舷健完成签到,获得积分10
3秒前
小王完成签到 ,获得积分10
3秒前
高小高完成签到,获得积分10
3秒前
稀饭完成签到,获得积分10
3秒前
懦弱的语柳完成签到 ,获得积分10
4秒前
无极微光的应助被含糊的晓凡采纳,获得20
4秒前
bbkillmm完成签到,获得积分10
4秒前
4秒前
bkagyin的应助被高兴的采文采纳,获得10
5秒前
echo完成签到,获得积分10
5秒前
5秒前
aixuexi*完成签到,获得积分10
6秒前
gxgxnn完成签到,获得积分10
6秒前
xiaobei88完成签到,获得积分10
6秒前
海林涵完成签到,获得积分10
7秒前
7秒前
7秒前
Zozo发布了新的文献求助20
7秒前
不明完成签到 ,获得积分10
7秒前
情怀的应助被蓝色天空采纳,获得10
7秒前
中级妖怪西西完成签到,获得积分10
8秒前
研友_ZGR0jn完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173692
求助须知:如何正确求助?哪些是违规求助? 9565811
关于积分的说明 21782566
捐赠科研通 7767850
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555860
邀请新用户注册赠送积分活动 2476903